Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep;43(9):1863-1868.
doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27.

Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial

Anna Pedret  1   2 , Rosa M Valls  3   4 , Lorena Calderón-Pérez  1   2 , Elisabet Llauradó  1   2 , Judit Companys  1   2 , Laura Pla-Pagà  1   2 , Ana Moragas  5   6   7 , Francisco Martín-Luján  5   6   8 , Yolanda Ortega  5   6   9 , Montse Giralt  1   2 , Antoni Caimari  1 , Empar Chenoll  10 , Salvador Genovés  10 , Patricia Martorell  10 , Francisco M Codoñer  11 , Daniel Ramón  1   10 , Lluís Arola  1   12 , Rosa Solà  1   2   13
Affiliations
Randomized Controlled Trial

Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial

Anna Pedret et al. Int J Obes (Lond). 2019 Sep.

Abstract

Background: The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown.

Objective: To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers.

Design: Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 1010 colony forming unit (CFU) of Ba8145, 1010 CFU of h-k Ba8145, or placebo (maltodextrin) for 3 months.

Results: Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003).

Conclusions: In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.

PubMed Disclaimer

Conflict of interest statement

Empar Chenoll, Salvador Genovés, Patricia Martorell, Francisco M. Codoñer and Daniel Ramón are employees of Biopolis SL/ADM or Lifesequencing/ADM, Valencia, Spain. All the other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Changes in anthropometric adiposity biomarkers from baseline to the end of the study. a body mass index, b waist circumference, c waist circumference/height ratio, d conicity index. * P < 0.05 for intra-treatment comparisons. # P < 0.05 for inter-treatment comparisons (vs. Placebo). ¥ P < 0.07 a trend for inter-treatment comparisons (vs Placebo)
See this image and copyright information in PMC

References

    1. WHO. Obesity and overweight. World Heal. Organ. 2017. http://www.who.int/mediacentre/factsheets/fs311/en/.
    1. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. doi: 10.4158/EP161365.GL. - DOI - PubMed
    1. Borgeraas H, Johnson LK, Skattebu J, Hertel JK, Hjelmesaeth J. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2018;19:219–32. doi: 10.1111/obr.12626. - DOI - PubMed
    1. Zorzela L, Ardestani SK, McFarland LV, Vohra S. Is there a role for modified probiotics as beneficial microbes: a systematic review of the literature. Benef Microbes. 2017;8:739–54. doi: 10.3920/BM2017.0032. - DOI - PubMed
    1. Martorell P, Llopis S, González N, Chenoll E, López-Carreras N, Aleixandre A, et al. Probiotic Strain Bifidobacterium animalis subsp. lactis CECT 8145 reduces fat content and modulates lipid metabolism and antioxidant response in Caenorhabditis elegans. J Agric Food Chem. 2016;64:3462–72. doi: 10.1021/acs.jafc.5b05934. - DOI - PubMed

Publication types